Replies to post #178532 on Biotech Values

[DewDiligence]

FDA awards BTD for B-I’s Idarucizumab, a Pradaxa antidote:

http://finance.yahoo.com/news/boehringer-ingelheims-investigational-antidote-pradaxa-120200790.html

The lack of an approved antidote has caused B-I to pay substantial legal fees in cases where Pradaxa patients bled to death (#msg-102641221).

As a direct thrombin inhibitor (rather than a FXa inhibitor), Pradaxa can’t be reversed by PTLA’s Andexanet Alfa.